A simulation‐based comparison of estimation methods for adaptive and classical group sequential clinical trials.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 3, p. 599, doi. 10.1002/pst.2188
- By:
- Publication type:
- Article
Works matching IS 15391604 AND DT 2022 AND VI 21 AND IP 3
Results: 13
1
2
Decision rules for identifying combination therapies in open‐entry, randomized controlled platform trials.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 3, p. 671, doi. 10.1002/pst.2194
- By:
- Publication type:
- Article
3
A targeted simulation‐extrapolation method for evaluating biomarkers based on new technologies in precision medicine.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 3, p. 584, doi. 10.1002/pst.2187
- By:
- Publication type:
- Article
4
Return‐to‐baseline multiple imputation for missing values in clinical trials.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 3, p. 641, doi. 10.1002/pst.2191
- By:
- Publication type:
- Article
5
An adaptive design for early clinical development including interim decision for single‐arm trial with external controls or randomized trial.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 3, p. 625, doi. 10.1002/pst.2190
- By:
- Publication type:
- Article
6
Estimation of a treatment policy estimand for time to event data using data collected post discontinuation of randomised treatment.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 3, p. 612, doi. 10.1002/pst.2189
- By:
- Publication type:
- Article
7
Bayesian MCPMod.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 3, p. 654, doi. 10.1002/pst.2193
- By:
- Publication type:
- Article
8
Regulatory issues and the potential use of Bayesian approaches for early drug approval systems in Japan.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 3, p. 691, doi. 10.1002/pst.2192
- By:
- Publication type:
- Article
9
Empirical likelihood confidence interval for sensitivity to the early disease stage.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 3, p. 566, doi. 10.1002/pst.2186
- By:
- Publication type:
- Article
10
Estimation of multivariate treatment effects in contaminated clinical trials.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 3, p. 535, doi. 10.1002/pst.2185
- By:
- Publication type:
- Article
11
Kernel hazard estimation for visualisation of the effect of a continuous covariates on time‐to‐event endpoints.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 3, p. 514, doi. 10.1002/pst.2183
- By:
- Publication type:
- Article
12
Issue Information.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 3, p. 511, doi. 10.1002/pst.2135
- Publication type:
- Article
13
Estimating the treatment effect for adherers using multiple imputation.
- Published in:
- Pharmaceutical Statistics, 2022, v. 21, n. 3, p. 525, doi. 10.1002/pst.2184
- By:
- Publication type:
- Article